Table 3 Outcomes
From: Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation
Parameters | Placebo group (N = 37) | Ganciclovir group (N = 39) | P Value |
|---|---|---|---|
Primary outcome | |||
Ventilator-free days on day 60 | 0 (0–43) | 10 (0–51) | 0.459 |
Secondary outcomes (post-randomization) | |||
Day-60 mortality, no. (%) | 16 (43.2) | 16 (41.0) | 0.845 |
Duration of MV | 20 (7–40) | 12 (6–29) | 0.246 |
ICU length of stay (from admission) | 44.0 (21.0–66.5) | 36.0 (24.0–51.0) | 0.377 |
ICU length of stay (from randomization) | 26.0 (11.0–50.0) | 17.0 (8.0–34.0) | 0.318 |
Hospitalization length (from admission) | 60.0 (33.0–75.5) | 65.0 (28.0–78.0) | 0.988 |
Hospitalization length (from randomization) | 42.0 (18.5–60.0) | 38.0 (13.0–60.0) | 0.945 |
HSV bronchopneumonitis, no. (%) | 1 (2.7) | 0 (0) | 0.487 |
Cytomegalovirus infection, no. (%) | 5 (13.5) | 1 (2.6) | 0.103 |
Ventilator-associated pneumonia, no. (%) | 15 (40.5) | 13 (33.3) | 0.515 |
Secondary bacteremia or fungemia, no. (%) | 8 (21.6) | 7 (17.9) | 0.688 |
ARDS post-randomization, no. (%) | 6 (16.2) | 6 (15.4) | 0.921 |
Milda | 0 | 0 | |
Moderatea | 3 | 3 | |
Severea | 3 | 3 | |
Septic shock post-randomization, no. (%) | 14 (37.8) | 13 (33.3) | 0.682 |
Renal replacement therapy until day 28, no. (%) | 18 (48.6) | 16 (41.0) | 0.504 |
Number of days with study drug, no. (%) | 14 (7.5–14) | 14 (6.0–14) | 0.991 |